Identification of (R)-N-(4-(4-methoxyphenyl)thiazol-2-yl)-1-tosylpiperidine-2-carboxamide, ML277, as a novel, potent and selective Kv7.1 (KCNQ1) potassium channel activator
摘要:
A high-throughput screen utilizing a depolarization-triggered thallium influx through KCNQ1 channels was developed and used to screen the MLSMR collection of over 300,000 compounds. An iterative medicinal chemistry approach was initiated and from this effort, ML277 was identified as a potent activator of KCNQ1 channels (EC50 = 260 nM). ML277 was shown to be highly selective against other KCNQ channels (> 100-fold selectivity versus KCNQ2 and KCNQ4) as well as against the distantly related hERG potassium channel. (C) 2012 Elsevier Ltd. All rights reserved.
[EN] METHODS OF TREATING NEUROPSYCHIATRIC DISORDERS<br/>[FR] MÉTHODES DE TRAITEMENT DE TROUBLES NEUROPSYCHIATRIQUES
申请人:UNIV ROCHESTER
公开号:WO2018209022A2
公开(公告)日:2018-11-15
The present disclosure is directed to a method of treating a neuropsychiatric disorder. This method involves selecting a subject having the neuropsychiatric disorder and administering to the selected subject a preparation of glial progenitor cells at a dosage effective to treat the neuropsychiatric disorder in the subject. Another aspect of the disclosure is directed to a method of treating a neuropsychiatric disorder that includes selecting a subject having the neuropsychiatric disorder and administering, to the selected subject, a potassium (K+) channel activator at a dosage effective to restore normal brain interstitial glial K+ levels in the selected subject and treat the neuropsychiatric disorder is also disclosed.
[EN] COMPOSITIONS AND METHODS FOR TARGETED PROTEIN STABILIZATION BY REDIRECTING ENDOGENOUS DEUBIQUITINASES<br/>[FR] COMPOSITIONS ET MÉTHODES DE STABILISATION DE PROTÉINES CIBLÉES PAR RÉORIENTATION DE DÉSUBIQUITINASES ENDOGÈNES
申请人:UNIV COLUMBIA
公开号:WO2021146390A1
公开(公告)日:2021-07-22
The present disclosure provides, inter alia, bivalent nanobody molecules and methods for treating or ameliorating the effects of a disease, such as long QT syndrome, or cystic fibrosis, in a subject, using the bivalent nanobody molecules disclosed herein. Also provided are methods of identifying and preparing nanobody binders that target proteins of interest.
WO2022272133A2
申请人:——
公开号:WO2022272133A2
公开(公告)日:2022-12-29
Identification of (R)-N-(4-(4-methoxyphenyl)thiazol-2-yl)-1-tosylpiperidine-2-carboxamide, ML277, as a novel, potent and selective Kv7.1 (KCNQ1) potassium channel activator
作者:Margrith E. Mattmann、Haibo Yu、Zhihong Lin、Kaiping Xu、Xiaofang Huang、Shunyou Long、Meng Wu、Owen B. McManus、Darren W. Engers、Uyen M. Le、Min Li、Craig W. Lindsley、Corey R. Hopkins
DOI:10.1016/j.bmcl.2012.07.060
日期:2012.9
A high-throughput screen utilizing a depolarization-triggered thallium influx through KCNQ1 channels was developed and used to screen the MLSMR collection of over 300,000 compounds. An iterative medicinal chemistry approach was initiated and from this effort, ML277 was identified as a potent activator of KCNQ1 channels (EC50 = 260 nM). ML277 was shown to be highly selective against other KCNQ channels (> 100-fold selectivity versus KCNQ2 and KCNQ4) as well as against the distantly related hERG potassium channel. (C) 2012 Elsevier Ltd. All rights reserved.